What does APOTHEEK ROZEMAAI do?

APOTHEEK ROZEMAAI is a pharmacy in Antwerpen. Private Limited, started on 2 March 2010, 1 establishment.

What is the address of APOTHEEK ROZEMAAI?

The registered office of APOTHEEK ROZEMAAI is located at Jef Van Hoofstraat 2, 2180 Antwerpen.

Is APOTHEEK ROZEMAAI still active?

Yes. According to the CBE (5 November 2026) APOTHEEK ROZEMAAI is active, legal situation “Normale toestand”, started on 2 March 2010.

Is APOTHEEK ROZEMAAI registered on Peppol?

Yes, APOTHEEK ROZEMAAI is registered on the Peppol network with ID 0208:0823649962.

What is the enterprise number of APOTHEEK ROZEMAAI?

The enterprise number of APOTHEEK ROZEMAAI is BE0823649962.

When was APOTHEEK ROZEMAAI founded?

APOTHEEK ROZEMAAI was founded on 2 March 2010.

Who are the directors of APOTHEEK ROZEMAAI?

According to the 2025 annual accounts, the directors of APOTHEEK ROZEMAAI are: Ibex Care BV.

Is APOTHEEK ROZEMAAI a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 2 March 2010; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account; 1 events from the Belgian Official Gazette processed.

How much profit did APOTHEEK ROZEMAAI make in 2025?

APOTHEEK ROZEMAAI recorded a loss after taxes of € 32,085 in financial year 2025.

What is the revenue of APOTHEEK ROZEMAAI?

As a small company, APOTHEEK ROZEMAAI is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 58,047.

How much does an employee at APOTHEEK ROZEMAAI earn?

The average wage cost per full-time employee at APOTHEEK ROZEMAAI was € 55,200 in 2025: staff costs of € 71,700 for 1.3 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does APOTHEEK ROZEMAAI have?

According to the 2025 annual accounts, APOTHEEK ROZEMAAI has 1.3 full-time equivalents (FTE).

APOTHEEK ROZEMAAI (Private Limited) - Antwerpen

Dossier APOTHEEK ROZEMAAI, printed on 5 November 2026 from databakkes.be/en/0823649962/apotheek-rozemaai. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Two loss years in a row NBB

Negative result in 2024 and 2025.

Financials

Financial year 2025

APOTHEEK ROZEMAAI from Antwerpen, company number BE0823649962, closed financial year 2025 with a result of € -32,085 after tax. For that financial year APOTHEEK ROZEMAAI recorded a gross margin of € 58,047 and equity of € 133,805. Compared with financial year 2024, the result moved from € -69,797 to € -32,085. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 18, 2026.

What it is worth Healthy

€ 133,805

▼ 19% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -32,085

▲ 54 % less loss than in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 56,666

▼ 7% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € 115,205.

People and assets in 2025

Full-time equivalents

1.3

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 71,700

▲ 1% vs 2024

€ 55,200 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 87,554

▼ 4% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Wages and social charges

€ 10,638

▲ 9% vs 2024

Wages, holiday pay and social contributions still to pay. No outstanding taxes.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 143,404 Gross margin 2022: € 143,404 First fiscal year in the series	€ 38,004 Gross margin 2023: € 38,004 ▼ 73% vs 2022 (€ 143,404) Unfavourable step	€ 22,293 Gross margin 2024: € 22,293 ▼ 41% vs 2023 (€ 38,004) Unfavourable step	€ 58,047 Gross margin 2025: € 58,047 ▲ 160% vs 2024 (€ 22,293) Favourable step	▲ 160%
Profit after taxes	€ 30,236 Profit after taxes 2022: € 30,236 First fiscal year in the series	€ -22,331 Profit after taxes 2023: € -22,331 ▼ € 52,567 vs 2022 (€ 30,236) Unfavourable step	€ -69,797 Profit after taxes 2024: € -69,797 ▼ € 47,466 vs 2023 (€ -22,331) Unfavourable step	€ -32,085 Profit after taxes 2025: € -32,085 ▲ € 37,712 vs 2024 (€ -69,797) Favourable step	▲ € 37,712
Equity	€ 258,017 Equity 2022: € 258,017 First fiscal year in the series	€ 235,686 Equity 2023: € 235,686 ▼ 9% vs 2022 (€ 258,017) Unfavourable step	€ 165,889 Equity 2024: € 165,889 ▼ 30% vs 2023 (€ 235,686) Unfavourable step	€ 133,805 Equity 2025: € 133,805 ▼ 19% vs 2024 (€ 165,889) Unfavourable step	▼ 19%
Total debts	€ 205,349 Total debts 2022: € 205,349 First fiscal year in the series	€ 161,169 Total debts 2023: € 161,169 ▼ 22% vs 2022 (€ 205,349) Favourable step	€ 136,957 Total debts 2024: € 136,957 ▼ 15% vs 2023 (€ 161,169) Favourable step	€ 173,980 Total debts 2025: € 173,980 ▲ 27% vs 2024 (€ 136,957) Unfavourable step	▲ 27%
Cash	€ 217,011 Cash 2022: € 217,011 First fiscal year in the series	€ 135,470 Cash 2023: € 135,470 ▼ 38% vs 2022 (€ 217,011) Unfavourable step	€ 60,748 Cash 2024: € 60,748 ▼ 55% vs 2023 (€ 135,470) Unfavourable step	€ 56,666 Cash 2025: € 56,666 ▼ 7% vs 2024 (€ 60,748) Unfavourable step	▼ 7%
Retained profit	€ 239,417 Retained profit 2022: € 239,417 First fiscal year in the series	€ 217,086 Retained profit 2023: € 217,086 ▼ 9% vs 2022 (€ 239,417) Unfavourable step	€ 147,289 Retained profit 2024: € 147,289 ▼ 32% vs 2023 (€ 217,086) Unfavourable step	€ 115,205 Retained profit 2025: € 115,205 ▼ 22% vs 2024 (€ 147,289) Unfavourable step	▼ 22%
Dividend	€ 62,600 Dividend 2022: € 62,600 First fiscal year in the series	€ 0 Dividend 2023: € 0 ▼ 100% vs 2022 (€ 62,600) Unchanged	€ 0 Dividend 2024: € 0 Unchanged (€ 0) Unchanged	€ 0 Dividend 2025: € 0 Unchanged (€ 0) Unchanged
Bank debt	€ 56,080 Bank debt 2022: € 56,080 First fiscal year in the series	€ 34,765 Bank debt 2023: € 34,765 ▼ 38% vs 2022 (€ 56,080) Favourable step	€ 10,225 Bank debt 2024: € 10,225 ▼ 71% vs 2023 (€ 34,765) Favourable step	€ 0 Bank debt 2025: € 0 ▼ 100% vs 2024 (€ 10,225) Favourable step	▼ 100%
Balance sheet total	€ 463,366 Balance sheet total 2022: € 463,366 First fiscal year in the series	€ 396,855 Balance sheet total 2023: € 396,855 ▼ 14% vs 2022 (€ 463,366) Unchanged	€ 302,846 Balance sheet total 2024: € 302,846 ▼ 24% vs 2023 (€ 396,855) Unchanged	€ 307,785 Balance sheet total 2025: € 307,785 ▲ 2% vs 2024 (€ 302,846) Unchanged	▲ 2%
Employees (FTE)	1.6 Employees (FTE) 2022: 1.6 First fiscal year in the series	0.9 Employees (FTE) 2023: 0.9 ▼ 0.7 vs 2022 (1.6) Unchanged	1.3 Employees (FTE) 2024: 1.3 ▲ 0.4 vs 2023 (0.9) Unchanged	1.3 Employees (FTE) 2025: 1.3 Unchanged (1.3) Unchanged

Key figures of APOTHEEK ROZEMAAI, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to APOTHEEK ROZEMAAI?

What happened at APOTHEEK ROZEMAAI in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Aug 18, 2026 New annual accounts for financial year 2025: loss of € 32,085. filed late Source: NBB ↗
2022 Ibex Care BV became a director. NBB
May 1, 2010 New establishment in Antwerpen. KBO
Mar 16, 2010 Incorporation, published in the Gazette. Source: Staatsblad ↗

In short

From € 30,236 profit in 2022 to € 32,085 loss in 2025.

Paid € 11,539 in corporate taxes since 2022.

Best year ever: 2022, with € 30,236 profit.

On average € 44,700 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

Ibex Care 100%

The stake of Ibex Care comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

APOTHEEK ROZEMAAI

Behind APOTHEEK ROZEMAAI is Ibex Care BV. The shares are held by Ibex Care (100%).

Directors

According to the 2025 annual accounts

Ibex Care BV

Director · represented by De Roeve Cindy

Also active at: Symbiose Health Care

since 2022

Shareholders

Ibex Care

100%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Jef Van Hoofstraat 2

2180 Antwerpen

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Shareholders according to the Official Gazette deeds

Who contributed at incorporation and at capital increases, with the deed as source. Later share transfers are not published in the Gazette.

Incorporation

16 March 2010 Source: Deed ↗

VERLINDEN Kathleen(oprichter-vennoot) 100%

Details

Company number: 0823.649.962
VAT number: BE 0823.649.962
Registered office: Jef Van Hoofstraat 2, 2180 Antwerpen
Names & denominations: APOTHEEK ROZEMAAI
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 2 March 2010
Peppol: Active · Active since 21 Nov 2025
Activities · NACE: Detailhandel in farmaceutische producten

View on CBE Public ↗ Annual accounts (NBB) ↗